Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
Initial clinical sites activated and patient screening underway
Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH.
“NASH is the quintessential complex disease, involving the dysregulation of numerous biological pathways and impacting an enormous, heterogenous global population,” said Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visiting professor of Hepatology at the University of Oxford, UK and the principal investigator of EMMPACT. “These factors have confounded many physicians and drug developers in the past. Given its multi-modal mechanism, the activity and tolerability seen in past clinical studies and the presumed safety of its underlying amino acids, AXA1125 holds the potential to serve as an ideal first-line NASH agent. We are excited to have EMMPACT underway and are eager to gauge AXA1125’s histological impact.”

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , San Antonio , Texas , Alison Schecter , Stephena Harrison , Pinnacle Clinical Research , University Of Oxford , Drug Administration , Global Liver Institute , Medical Director , Bill Hinshaw , Chief Executive Officer , Non Alcoholic Steatohepatitis , Endogenous Metabolic Modulators , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , கேம்பிரிட்ஜ் , கேம்பிரிட்ஜ்ஷைர் , ஒன்றுபட்டது கிஂக்டம் , சான் அன்டோனியோ , டெக்சாஸ் , அலிசன் ஸ்கெக்டர் , உச்சம் மருத்துவ ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் , உலகளாவிய கல்லீரல் நிறுவனம் , மருத்துவ இயக்குனர் , ர சி து ஹின்ஷா , தலைமை நிர்வாகி அதிகாரி , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கை ,